Please login to the form below

Not currently logged in
Email:
Password:

Juventas

This page shows the latest Juventas news and features for those working in and with pharma, biotech and healthcare.

Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

Astellas bulks up immuno-oncology pipeline with $665m Xyphos deal

This includes a deal made in  2018, when Astellas bought out gene therapy biotech Juventas for an exclusive option on its non-viral gene therapy JVS-100.

Latest news

  • Astellas makes another gene therapy play with Juventas deal Astellas makes another gene therapy play with Juventas deal

    Targeting faecal incontinence, which affects 50m worldwide. Astellas has made another deal in the gene therapy category, licensing a candidate for treating faecal incontinence from US biotech Juventas Therapeutics. ... Juventas has previously shown that

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Among these, Juventas Therapeutics' non-viral gene therapy JVS-100 - which expresses stromal cell-derived factor-1 (SDF-1) and activates the body's own tissue repair pathways - has been

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...